Education
About Us
Working with TipRanks
Follow Us
Coherus Biosciences (CHRS)
NASDAQ:CHRS
Earnings Data
Report Date
Mar 17, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.34Last Year’s EPS
-0.44Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook, with strong financial performance, strategic focus on pipeline development, and effective market expansion strategies. However, some challenges remain in regional sales discrepancies and community physician engagement.Company Guidance
Strong Financial Performance
LOQTORZI net revenue grew to $11.2 million, a 12% increase quarter-over-quarter and 92% increase year-over-year. The company has significantly improved its balance sheet with $192 million in cash and investments and a 69% decrease in non-TSA liabilities.
Pipeline Progress and Strategic Focus
Coherus Oncology is advancing its clinical trials, particularly with LOQTORZI in combination with proprietary assets like CHS-114 and casdozokitug. Enrollment is on track, and the company is pursuing multiple cancer indications, demonstrating its scientific leadership.
Market Expansion and Sales Strategy
The company is expanding its sales force by 15% and implementing a remote sales team to increase reach, particularly in the community setting where awareness of LOQTORZI's clinical benefits needs reinforcement.
Reduction in Operating Expenses
SG&A expenses decreased by 11% compared to last year due to decreased headcount, reflecting the company's focus on spending discipline and operational streamlining.
CHRS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CHRS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | $1.49 | $1.34 | -10.07% |
Aug 07, 2025 | $0.88 | $0.82 | -6.82% |
May 12, 2025 | $1.02 | $0.82 | -19.61% |
Mar 10, 2025 | $1.04 | $1.05 | +0.96% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Coherus Biosciences (CHRS) report earnings?
Coherus Biosciences (CHRS) is schdueled to report earning on Mar 17, 2026, After Close (Confirmed).
What is Coherus Biosciences (CHRS) earnings time?
Coherus Biosciences (CHRS) earnings time is at Mar 17, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CHRS EPS forecast?
CHRS EPS forecast for the fiscal quarter 2025 (Q4) is -0.34.